Lise M. van Wijk

Capturing breast cancers’ copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond

Claire J.H. Kramer, Lise M. van Wijk, Dina Ruano, S. Gelpke-Vermeulen et autres

nl, se (code pays fourni par la source)

Business case for psychosocial interventions in clinics: potential for decrease in treatment discontinuation and costs

Ad A. Kaptein, Joyce Harper, Grada van den Dool, Marieke Schoonenberg et autres

nl, us, gb (code pays fourni par la source)

Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue

Lise M. van Wijk, Sylvia Vermeulen, Natalja T. ter Haar, Claire J.H. Kramer et autres

PURPOSE: BRCA-deficient breast cancers (BC) are highly sensitive to platinum-based chemotherapy and PARP inhibitors due to their deficiency in the homologous recombination (HR) pathway. However, HR deficiency (HRD) extends beyond BRCA-associated BC, highlighting the need for a sensitive method to enrich for …

nl (code pays fourni par la source)

The PCQ-Infertility Revised: A New Digital Instrument to Measure Treatment Satisfaction of Fertility Patients

Lotte van der Kolk, Ellen G. M. Smit, Josée Bloemer, Lise M. van Wijk

Background: One of the key dimensions of healthcare quality is patient-centeredness, which represents how well healthcare is geared towards patients' needs and wishes. Many questionnaires that measure the patient-centeredness are long and complicated, eliciting non-response or careless responding. Moreover, responses to some …

nl (code pays fourni par la source)

Supplementary Table S3 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres

Table S3 gives an overview of the detected class 3, 4 and 5 variants in the final cohort.

Supplementary Methods from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres

Supplementary Material and Methods

Supplementary Figure S2 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres

Figure S2 shows that their is an unbiased natural devision between samples analyes by the oncoscan platform and the CGH Agilent platform.

Supplementary Table S2 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres

Table S2 shows the clinicopathological characteristics of the homologous recombination intermediate cases.

Supplementary Table S1 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres

Table S1 shows the clinicopathological characteristics of the cases included in final analysis.

Data from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres

AbstractPurpose: The elevated levels of somatic copy-number alterations (SCNAs) in a subset of high-risk endometrial cancers are suggestive of defects in pathways governing genome integrity. We sought to assess the prevalence of homologous recombination deficiency (HRD) in endometrial cancers and its association …

Data from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres

AbstractPurpose: The elevated levels of somatic copy-number alterations (SCNAs) in a subset of high-risk endometrial cancers are suggestive of defects in pathways governing genome integrity. We sought to assess the prevalence of homologous recombination deficiency (HRD) in endometrial cancers and its association …

Supplementary Figure S1 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten et autres

Figure S1 shows that the Oncoscan and CGH agilent platform yield similar results.